A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
A phase 2 trial of Ziftomenib in acute myeloid leukaemia, run by Kyowa Kirin Co., Ltd., now recruiting.
Overview
A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia is a phase 2 interventional study registered as NCT07623616 by Kyowa Kirin Co., Ltd., with 6 participants planned, started 2026-04-23 and due to reach its primary completion in 2027-03. Interventions recorded: ziftomenib.
Similar pages
not linked directly; found by shared links- TrialA Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms
Shares Kyowa Kirin and the tag pipeline.
- TrialStudies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Shares Ziftomenib, Acute myeloid leukaemia and the tag pipeline.
- TrialMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialPhase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialClinical Study of U32 in Patients With Acute Myeloid Leukemia
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialAn Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialFirst-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
Shares Acute myeloid leukaemia and the tag pipeline.
- TrialA Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Shares Acute myeloid leukaemia and the tag pipeline.